Central Pharmaceutical Joint Stock Company No3 (HNX:DP3)
Vietnam · Delayed Price · Currency is VND 60,300
-300 (-0.50%)
At close: Nov 3, 2026
HNX:DP3 Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 524,408 | 437,927 | 417,485 | 409,731 | 485,074 | 381,077 | |
Revenue Growth | 24.11% | 4.90% | 1.89% | -15.53% | 27.29% | -3.70% |
Cost of Revenue | 181,351 | 150,345 | 141,432 | 128,228 | 148,536 | 117,447 |
Gross Profit | 343,057 | 287,582 | 276,054 | 281,503 | 336,538 | 263,630 |
Selling, General & Admin | 107,807 | 117,331 | 139,372 | 144,618 | 208,717 | 151,491 |
Operating Expenses | 107,807 | 117,331 | 139,372 | 144,618 | 208,717 | 151,491 |
Operating Income | 235,250 | 170,252 | 136,682 | 136,885 | 127,821 | 112,139 |
Interest Expense | -1,884 | -694.75 | -161.5 | -1,594 | -6,475 | -449 |
Interest & Investment Income | 32,653 | 22,834 | 15,463 | 21,665 | 10,732 | 7,360 |
Currency Exchange Gain (Loss) | -41.77 | -64.63 | -133.63 | -15.04 | - | - |
Other Non Operating Income (Expenses) | 925.03 | 262.86 | -97.52 | 60.97 | 4,412 | -839.85 |
EBT Excluding Unusual Items | 266,902 | 192,589 | 151,752 | 157,001 | 136,490 | 118,210 |
Gain (Loss) on Sale of Assets | 30 | 30 | 163.2 | 2.28 | - | - |
Pretax Income | 266,932 | 192,619 | 151,915 | 157,003 | 136,490 | 118,210 |
Income Tax Expense | 50,933 | 36,546 | 30,743 | 31,740 | 27,665 | 23,905 |
Net Income | 215,999 | 156,073 | 121,172 | 125,263 | 108,824 | 94,305 |
Net Income to Common | 215,999 | 156,073 | 121,172 | 125,263 | 108,824 | 94,305 |
Net Income Growth | 67.34% | 28.80% | -3.27% | 15.11% | 15.40% | -17.32% |
Shares Outstanding (Basic) | 21 | 21 | 21 | 21 | 23 | 21 |
Shares Outstanding (Diluted) | 21 | 21 | 21 | 21 | 23 | 21 |
Shares Change | - | - | - | -5.00% | 5.27% | -0.00% |
EPS (Basic) | 10046.49 | 7259.25 | 5635.90 | 5826.22 | 4808.40 | 4386.40 |
EPS (Diluted) | 10046.49 | 7259.25 | 5635.90 | 5826.22 | 4808.40 | 4386.40 |
EPS Growth | 67.34% | 28.80% | -3.27% | 21.17% | 9.62% | -17.32% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 101,882 | 143,919 | 90,452 | 146,699 | 84,126 | 25,862 |
Free Cash Flow Per Share | 4738.70 | 6693.91 | 4207.10 | 6823.21 | 3717.11 | 1202.91 |
Dividend Per Share | 4000.000 | 4000.000 | 3000.000 | 3000.000 | - | 2400.000 |
Dividend Growth | 33.33% | 33.33% | 0% | - | - | - |
Gross Margin | 65.42% | 65.67% | 66.12% | 68.70% | 69.38% | 69.18% |
Operating Margin | 44.86% | 38.88% | 32.74% | 33.41% | 26.35% | 29.43% |
Profit Margin | 41.19% | 35.64% | 29.02% | 30.57% | 22.43% | 24.75% |
Free Cash Flow Margin | 19.43% | 32.86% | 21.67% | 35.80% | 17.34% | 6.79% |
EBITDA | 247,550 | 182,653 | 149,622 | 150,864 | - | - |
EBITDA Margin | 47.21% | 41.71% | 35.84% | 36.82% | - | - |
D&A For EBITDA | 12,300 | 12,401 | 12,941 | 13,980 | - | - |
EBIT | 235,250 | 170,252 | 136,682 | 136,885 | 127,821 | 112,139 |
EBIT Margin | 44.86% | 38.88% | 32.74% | 33.41% | 26.35% | 29.43% |
Effective Tax Rate | 19.08% | 18.97% | 20.24% | 20.22% | 20.27% | 20.22% |
Revenue as Reported | 524,408 | 437,927 | 417,485 | 409,731 | 485,074 | 381,077 |